Incidental Accumulation of Fluciclovine in Neuroendocrine Tumour in a Patient with Oncological Duplicity

18F-fluciclovine is a PET radiopharmaceutical used for the detection of recurrent prostate cancer in adult men after primary curative treatment with suspicion of recurrence based on elevated prostate-specific antigen level. Several incidental uptakes of 18F-fluciclovine in other tumour types have been described in the literature so far – in breast cancer, hepatocellular carcinoma, and malignant melanoma. Our case report presents a patient with oncological duplicity (prostate gland carcinoma and newly diagnosed neuroendocrine tumour) and with accumulation of fluciclovine in pathologically proved neuroendocrine tumour, later imagined also by octreotide SPECT/CT. To our knowledge, this is the first case of fluciclovine accumulated in a neuroendocrine tumour described in the literature.

Download Full-text

Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma

Canadian Urological Association Journal ◽

10.5489/cuaj.86 ◽

2012 ◽

Vol 1 (3) ◽

Author(s):

Sanjeev Madaan, ◽

Victor Palit ◽

Patricia Gudgeon ◽

Chandra Shekhar Biyani

Keyword(s):

Prostate Gland ◽

Specific Antigen ◽

Malignant Ascites ◽

Prostatic Adenocarcinoma ◽

Second Line ◽

Antigen Level ◽

Review Of The Literature ◽

Clinical Progression ◽

Unusual Manifestation ◽

Omental Metastasis

Omental metastasis with malignant ascites from prostatic adenocarcinoma israre. This case report is about a patient who presented with a 24-hour historyof a swollen right leg. Clinical examination revealed a hard prostate and bloodbiochemistry demonstrated an elevated prostate specific antigen level. A Dopplerultrasound scan excluded deep venous thrombosis, but a CT scan of the abdomen revealed marked para-aortic lymphadenopathy and prostate gland biopsy confirmedprostatic adenocarcinoma. The patient was treated with goserelin. Three years later, he presented with ascites and an omental mass. Histology of theomental mass showed metastasis from the prostatic adenocarcinoma. He was treated with second-line hormonal therapy but died after 4 months. We discuss the clinical progression, with a review of the literature.

Download Full-text

The value of Gleason score and prostate-specific antigen level in predicting the need for a baseline nuclear bone scan in patients with newly diagnosed 84 prostate cancer cases

International Journal of Cancer Therapy and Oncology ◽

10.14319/ijcto.33.16 ◽

2015 ◽

Vol 3 (3) ◽

pp. 3316

Author(s):

Hind Chorfi

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Gleason Score ◽

Bone Scan ◽

Specific Antigen ◽

Prostate Specific Antigen Level ◽

Newly Diagnosed ◽

Antigen Level

Download Full-text

Recurrent Prostate Cancer Presenting as Multiple Lung Metastases with a Low Serum Prostate-specific Antigen Level 5 Years after Prostatectomy: A Case Report

Korean Journal of Medicine ◽

10.3904/kjm.2015.89.2.238 ◽

2015 ◽

Vol 89 (2) ◽

pp. 238-242

Author(s):

Yu Mi Ko ◽

Jung-eun Lee ◽

Ji Yeon Yoo ◽

Jinhee Park ◽

Sang Young Roh

Keyword(s):

Prostate Cancer ◽

Case Report ◽

Prostate Specific Antigen ◽

Lung Metastases ◽

Specific Antigen ◽

Prostate Specific Antigen Level ◽

Antigen Level ◽

Recurrent Prostate Cancer ◽

Serum Prostate Specific Antigen ◽

Low Serum

Download Full-text

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen level

British Journal of Cancer ◽

10.1038/sj.bjc.6690670 ◽

1999 ◽

Vol 81 (1) ◽

pp. 184-185 ◽

Cited By ~ 3

Author(s):

C A Coltman

Keyword(s):

Prostate Specific Antigen ◽

Prostate Gland ◽

Specific Antigen ◽

Elevated Serum ◽

Prostate Specific Antigen Level ◽

Antigen Level ◽

Serum Prostate Specific Antigen

Download Full-text

Study of prostatic pathology and its correlation with prostate specific antigen level

Journal of Pathology of Nepal ◽

10.3126/jpn.v7i1.16911 ◽

2017 ◽

Vol 7 (1) ◽

pp. 1074-1077 ◽

Cited By ~ 1

Author(s):

S Hirachand ◽

UMS Dangol ◽

S Pradhanang ◽

S Acharya

Keyword(s):

Benign Prostatic Hyperplasia ◽

Prostate Specific Antigen ◽

Prostate Gland ◽

Specific Antigen ◽

Prostatic Hyperplasia ◽

Prostate Specific Antigen Level ◽

Transurethral Resection Of Prostate ◽

Antigen Level ◽

Histological Lesion ◽

Serum Prostate Specific Antigen

Background: Diseases primarily inflicting prostate gland are inflammation, benign prostatic hyperplasia and cancer. Prostate specific antigen is a protein produced by the cells of prostate gland. It has been widely used in the diagnosis and management of patients with prostatic cancer. The aim this study was to determine the correlation between serum prostate specific antigen level and histological findings in biopsy specimens of men with prostatic disease.Materials and methods: This study was carried out at Kathmandu Medical College and Teaching Hospital, department of Pathology over a period of 2 years. One hundred and twenty eight cases with prostatic lesions were included in this study. Prostate specific antigen values of these cases were recorded before the surgical process. Histology of the tissue samples collected after transurethral resection of prostate was studied and relationship with prostate specific antigen level were analyzed.Results: Benign prostatic hyperplasia was the most common histological lesion encountered (n=95; 74.22%). Prostatic adenocarcinomas were seen a decade older than those with benign lesions. Maximum number of the benign cases had the Prostate specific antigen range of 0-7ng/ml. Most of the prostatic intraepithelial neoplasia lesions were seen within the PSA range of 0-7ng/ml and adenocarcinoma in the range of >20ng/ml.Conclusion: Prostate specific antigen is specific for the prostate but not for prostate cancer. Both benign and malignant lesions in prostate can cause increase in serum prostate specific antigen levels, but the chances of malignancy it rising level.

Download Full-text